A Review of the Current Status of G6PD Deficiency Testing to Guide Radical Cure Treatment for Vivax Malaria
<i>Plasmodium vivax</i> malaria continues to cause a significant burden of disease in the Asia-Pacific, the Horn of Africa, and the Americas. In addition to schizontocidal treatment, the 8-aminoquinoline drugs are crucial for the complete removal of the parasite from the human host (radi...
Main Authors: | Arkasha Sadhewa, Sarah Cassidy-Seyoum, Sanjaya Acharya, Angela Devine, Ric N. Price, Muthoni Mwaura, Kamala Thriemer, Benedikt Ley |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Pathogens |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-0817/12/5/650 |
Similar Items
-
Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)
by: Kamala Thriemer, et al.
Published: (2022-05-01) -
Adherence to 14-day radical cure for Plasmodium vivax malaria in Papua, Indonesia: a mixed-methods study
by: Annisa Rahmalia, et al.
Published: (2023-05-01) -
A randomised controlled trial to compare the efficacy, safety, and tolerability of low dose, short course primaquine in adults with uncomplicated P. vivax malaria in two hospitals in India
by: Sundus Shafat Ahmad, et al.
Published: (2024-02-01) -
A review of the current status of G6PD deficiency testing to guide radical cure treatment for vivax malaria
by: Sadhewa, A, et al.
Published: (2023) -
Diagnostic Practices and Treatment for <i>P. vivax</i> in the InterEthnic Therapeutic Encounter of South-Central Vietnam: A Mixed-Methods Study
by: Thuan Thi Nguyen, et al.
Published: (2020-12-01)